Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Pediatrics
Volume 2016, Article ID 8712962, 3 pages
http://dx.doi.org/10.1155/2016/8712962
Case Report

Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment

1Department of Pediatric Cardiology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey
2Department of Neonatology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey
3Department of Pediatric Cardiology, Cerrahpasa Medical Faculty, Istanbul University, 34098 Istanbul, Turkey
4Department of Pediatric Hematology-Oncology, Kanuni Suleyman Teaching and Research Hospital, 34303 Istanbul, Turkey

Received 23 February 2016; Revised 17 May 2016; Accepted 30 May 2016

Academic Editor: Ozgur Cogulu

Copyright © 2016 Helen Bornaun et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Cardiac rhabdomyoma often shows spontaneous regression and usually requires only close follow-up. However, patients with symptomatic inoperable rhabdomyomas may be candidates for everolimus treatment. Our patient had multiple inoperable cardiac rhabdomyomas causing serious left ventricle outflow-tract obstruction that showed a dramatic reduction in the size after everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor. After discontinuation of therapy, an increase in the diameter of masses occurred and everolimus was restarted. After 6 months of treatment, rhabdomyomas decreased in size and therapy was stopped. In conclusion, everolimus could be a possible novel therapy for neonates with clinically significant rhabdomyomas.